FilingJul 22, 2026
Regulatory filing — FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer▸
medium impact
ApprovalJul 15, 2026
FDA approval — Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC▸
high impact
ApprovalJul 14, 2026
FDA approval — Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen▸
high impact
ApprovalJul 10, 2026
FDA approval — U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regar…▸
high impact
ApprovalJul 08, 2026
FDA approval — Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?▸
high impact
ApprovalJul 06, 2026
FDA approval — Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer▸
high impact
Data +Jun 25, 2026
Positive data — Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative▸
high impact
ApprovalJun 24, 2026
FDA approval — FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance▸
high impact
EarningsMay 05, 2026
Q1 2026 report-1.3%muted
EarningsFeb 03, 2026
FY 2025 report+5.6%positive
EarningsNov 04, 2025
Q3 2025 report+2.3%muted
EarningsAug 05, 2025
Q2 2025 report-0.7%muted
EarningsApr 29, 2025
Q1 2025 report+1.7%muted
EarningsFeb 04, 2025
FY 2024 report-0.5%muted
EarningsOct 29, 2024
Q3 2024 report-1.3%muted
EarningsJul 30, 2024
Q2 2024 report-3.0%negative